BRÈVE

sur Berlin Cures Holding AG

Berlin Cures Announces Changes to Board of Directors to Propel Development of BC 007

Berlin Cures Holding AG has appointed Craig T. Basson, Gerrard Terlouw, and Oliver von Stein to its Board of Directors. These changes aim to advance the development of BC 007, the company's lead drug candidate currently in Phase II trials for Long COVID.

Craig T. Basson brings over 25 years of experience in cardiovascular medicine. Gerrard Terlouw has two decades of corporate and business development expertise in the pharmaceutical industry. CEO Oliver von Stein adds his extensive management experience to the board.

The company emphasizes the importance of cardiovascular disease and Long COVID as strategic priorities. The new board members are expected to enhance the preparation for the Long COVID Phase II trial read-out and future development strategies.

Ulf Berg, Johannes Müller, and Georg Nederegger are stepping down from the board. Müller will continue as Chief Science Officer, contributing to the company's research efforts.

Berlin Cures uses innovative aptamer-based drugs targeting harmful autoantibodies in autoimmune diseases. In addition to Long COVID, BC 007 also addresses heart failure and other conditions.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Berlin Cures Holding AG